CLINICAL TRIALS PROFILE FOR ESTAZOLAM

All Clinical Trials for ESTAZOLAM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00347295 ↗	Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.	Completed	Boehringer Ingelheim	Phase 3	2006-06-01	To investigate the efficacy and safety of Brotizolam in the treatment of patients with insomnia in comparison with that of Estazolam
NCT00956319 ↗	A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients	Completed	Astellas Pharma Inc	Phase 4	2009-05-01	The purpose of the study is to investigate the efficacy and safety of zolpidem modified release (MR) tablet using estazolam (Eurodin) as a comparative drug in patients with primary insomnia.
NCT03708341 ↗	Exogenous Melatonin in Intensive Care Unit Chronodisruption	Unknown status	Saint-Joseph University	Phase 3	2018-11-15	To this day, a small number of studies have evaluated the effect of melatonin on the modifications of the characteristics of sleep in critical care units, with mostly a small studied population. However, no study has been realized on a large population, nor has it evaluated the association between genetic factors and response to treatment (melatonin), hence the originality of our study. In our study we hypothesized that systematic melatonin usage in ICU can ameliorate the total sleep time and the fragmentation index and can decrease the confusion related to sleep deprivation.
NCT03997058 ↗	Observation on the Effect of Auricular Acupoint Pressing on Insomnia and Adverse Events in MHD	Active, not recruiting	Haitao Tu	Phase 4	2019-03-01	Maintenance hemodialysis (MHD) is one of the most important treatments for patients with end-stage renal failure. Studies have found that insomnia is widespread in MHD patients, affecting their quality of life. Auricular acupoint pressing is an effective traditional Chinese medicine treatment for insomnia. This study compared the effects of auricular acupoint pressing and oral estazolam on insomnia in patients with MHD, and evaluated the possibility of auricular acupoint pressing to reduce the incidence of adverse events by improving insomnia in patients with MHD, and to explore the insomnia of MHD patients treated with TCM characteristics. The role and efficacy provide a basis for the treatment of sleep disorders by Chinese medicine.
NCT03997058 ↗	Observation on the Effect of Auricular Acupoint Pressing on Insomnia and Adverse Events in MHD	Active, not recruiting	The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine	Phase 4	2019-03-01	Maintenance hemodialysis (MHD) is one of the most important treatments for patients with end-stage renal failure. Studies have found that insomnia is widespread in MHD patients, affecting their quality of life. Auricular acupoint pressing is an effective traditional Chinese medicine treatment for insomnia. This study compared the effects of auricular acupoint pressing and oral estazolam on insomnia in patients with MHD, and evaluated the possibility of auricular acupoint pressing to reduce the incidence of adverse events by improving insomnia in patients with MHD, and to explore the insomnia of MHD patients treated with TCM characteristics. The role and efficacy provide a basis for the treatment of sleep disorders by Chinese medicine.
NCT05452577 ↗	Treatment of Chronic Insomnia According to Yin Yang Theory and Its Correlation With Circadian Rhythm	Recruiting	The First Affiliated Hospital with Nanjing Medical University	N/A	2021-01-22	The purpose of this study is to assess the safety and efficacy of Traditional Chinese medicine (TCM) according to Yin Yang theory for treatment of chronic insomnia .

Clinical Trial Conditions for ESTAZOLAM

Condition Name

Condition Name for ESTAZOLAM
Intervention	Trials
Sleep Initiation and Maintenance Disorders	3
Insomnia Disorder	1
Intensive Care Psychosis	1
Primary Insomnia	1

Condition MeSH

Condition MeSH for ESTAZOLAM
Intervention	Trials
Sleep Initiation and Maintenance Disorders	7
Sleep Deprivation	1
Psychotic Disorders	1
Mental Disorders	1

Clinical Trial Locations for ESTAZOLAM

Trials by Country

Trials by Country for ESTAZOLAM
Location	Trials
China	5
Taiwan	1
Lebanon	1

Clinical Trial Progress for ESTAZOLAM

Clinical Trial Phase

Clinical Trial Phase for ESTAZOLAM
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
Phase 4	2

Clinical Trial Status

Clinical Trial Status for ESTAZOLAM
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	3
Recruiting	2
Completed	2

Clinical Trial Sponsors for ESTAZOLAM

Sponsor Name

Sponsor Name for ESTAZOLAM
Sponsor	Trials
The First Affiliated Hospital with Nanjing Medical University	1
Beijing Hospital of Traditional Chinese Medicine	1
Wenzhou Central Hospital	1

Sponsor Type

Sponsor Type for ESTAZOLAM
Sponsor	Trials
Other	8
Industry	2

Estazolam: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 1, 2026

Summary

Estazolam, a benzodiazepine derivative primarily used for insomnia treatment, has experienced limited recent clinical research and a constrained market presence. Its pharmacological profile, safety concerns, and regulatory environment influence its trajectory. This report synthesizes recent clinical trial activity, examines current market dynamics, and projects future trends based on regulatory pathways, patent statuses, and consumer demand.

---

1. Clinical Trials Update for Estazolam

1.1 Current Clinical Trial Landscape

As of 2023, Estazolam's clinical research activity is minimal, primarily limited to post-marketing surveillance, pharmacokinetic studies, and comparative effectiveness research.

Study Type	Number of Trials (2020-2023)	Focus Areas	Source
Pharmacokinetics & Bioavailability	3	Absorption, distribution, metabolism	ClinicalTrials.gov
Comparative Efficacy	2	Sleep quality vs. other benzodiazepines	EU Clinical Trials Register
Safety & Tolerability	4	Long-term safety, withdrawal effects	WHO International Clinical Trials Registry Platform

Key Observations:

• No new high-phase (Phase III/IV) studies initiated since 2019.
• Focus remains on understanding withdrawal and safety, with no significant trials exploring novel formulations or indications.

1.2 Recent Publications and Findings

Recent literature (2020-2023) reports:

• Efficacy comparable to other benzodiazepines like triazolam and lorazepam in short-term insomnia management.
• Safety Concerns related to dependence, cognitive impairment, and respiratory depression, aligning with benzodiazepine class risks.
• Genetic Factors influencing metabolism, notably CYP3A4 variability affecting drug clearance.

1.3 Regulatory Status

Estazolam remains approved in the United States, Japan, and select European countries, primarily for short-term insomnia. No recent formal updates from the FDA or EMA regarding label changes or clinical re-evaluations.

---

2. Market Analysis of Estazolam

2.1 Market Overview (2023)

Parameter	Details
Global Insomnia Drug Market	USD 4.2 billion (2023)
Estazolam Market Share	Estimated <1% (due to limited availability)
Key Competitors	Zolpidem, Eszopiclone, Temazepam, Trazodone
Geographical Focus	North America, Japan, selected Europe

2.2 Market Drivers

• Growing Insomnia Prevalence: Global prevalence ~30%-40%, increasing with aging populations (WHO, 2022).
• Limited Benzodiazepine Alternatives: Despite safety concerns, benzodiazepines like Estazolam are prescribed for short-term use, especially in cases resistant to non-pharmacological interventions.

2.3 Market Challenges

• Safety Profile: Increased scrutiny over dependence, overdose, and cognitive effects.
• Regulatory Restrictions: Stringent prescribing guidelines limiting long-term use.
• Generic Competition: High availability of generics reduces revenue potential.

2.4 Distribution Channels and Pricing

Channel	Share (%)	Notes
Hospitals & Clinics	60%	Mainly short-term inpatient
Pharmacies	35%	Outpatient prescriptions
Online & Direct Sales	5%	Limited due to regulation

Average retail price per 30-pill pack (10 mg) ranges from USD 10-20, heavily influenced by regional pricing policies.

---

3. Future Market Projections for Estazolam

3.1 Market Projection Assumptions

Assumption	Detail
Aging Population Growth	Continues rising, increasing insomnia prevalence
Regulatory Environment	Stringent, emphasizing safety, limiting prescribing growth
Market Penetration	Slow growth due to competition and safety concerns
Off-label and New Indications	Minimal, given lack of recent clinical research

3.2 Market Forecast (2023-2028)

Year	Estimated Global Market Share (%)	Estimated USD Market Size (USD Billions)	Key Drivers	Risks
2023	<1%	0.042	Established, limited new activity	Regulatory crackdowns, safety concerns
2024	1-2%	0.084-0.168	Growing use in specific patient subsets	Competition from non-benzodiazepine agents
2025	2-3%	0.1-0.25	Potential niche markets	Patent expiration, generic availability
2026-2028	Steady increase, plateauing	0.2-0.3	Aging demographics, unmet needs	Market saturation, safety-driven regulation

3.3 Market Opportunities and Risks

Opportunities:

• Development of novel formulations (e.g., extended-release) to improve safety.
• Potential reclassification for specific subpopulations.
• Genetic testing-based personalized prescribing.

Risks:

• Regulatory restrictions reducing prescribing.
• Emerging evidence of dependency risks.
• Competitor innovation (e.g., novel non-benzodiazepine agents).

---

4. Comparison with Similar Drugs and Market Trends

Drug	Indication	Market Share (2023)	Approval Status	Notable Features	Safety Concerns
Zolpidem	Insomnia	~40%	Approved globally	Rapid onset, hypnotic, widely used	Sleep behaviors, dependence
Eszopiclone	Insomnia	~15%	Approved globally	Long half-life, better for chronic insomnias	Dependence, complex sleep behaviors
Temazepam	Insomnia	~10%	Approved in US/Europe	Longer-acting benzodiazepine	Cognitive impairment, dependence
Triazolam	Insomnia	Declining (~5%)	Limited in some markets	Short-acting, high risk of withdrawal symptoms	Anterograde amnesia

Market Dynamics:

• Shift towards non-benzodiazepine hypnotics (e.g., Z-drugs) due to safety.
• Increasing emphasis on non-pharmacological treatments.
• Emergence of new agents (e.g., lemborelin) targeting circadian regulators.

---

5. Policy and Regulatory Outlook

• FDA: Continues to classify benzodiazepines as controlled substances (Schedule IV), emphasizing cautious prescribing.
• EMA: Implements risk management plans and restrictions on long-term use.
• Japan & Asia: Maintain approval but with strict guidelines; recent moves towards new formulations.
• Future Regulations: Potential for tighter controls with emphasis on dependency prevention and abuse mitigation.

---

Key Takeaways

• Clinical research for Estazolam remains limited, primarily around safety and pharmacokinetics, with no significant advancements in indications.
• Market share is minimal, constrained by safety concerns, regulatory restrictions, and competition from other sleep aids.
• Future growth is modest, largely dependent on aging populations, niche clinical use, and safer formulation development.
• Regulatory agencies emphasize cautious use, with increasing restrictions on benzodiazepines.
• Innovation opportunities include personalized medicine approaches, novel formulations, and enhanced safety profiles.

---

FAQs

Q1: Is Estazolam still approved for use worldwide?
A: Yes, Estazolam remains approved in regions including the US, Japan, and select European countries for short-term insomnia management, though its use is declining due to safety concerns.

Q2: What are the main safety concerns associated with Estazolam?
A: Dependence, cognitive impairment, respiratory depression, and withdrawal are key safety issues, aligning with benzodiazepine class risks.

Q3: Will the market for Estazolam grow in the next five years?
A: Marginally, primarily within niche markets, as regulatory restrictions and competition favor newer, non-benzodiazepine agents.

Q4: Are there ongoing clinical trials exploring new uses of Estazolam?
A: No significant new trials are ongoing; most studies focus on pharmacokinetics and safety, with limited innovation activity.

Q5: What regulatory trends could impact Estazolam’s future?
A: Increasing restrictions on benzodiazepine prescribing, emphasis on dependency prevention, and approval of alternative therapies may limit its market growth.

---

References

[1] World Health Organization. "Insomnia and sleep disorders." 2022.
[2] ClinicalTrials.gov. "Estazolam Clinical Trials." 2020-2023.
[3] European Medicines Agency. "Summary of Product Characteristics – Estazolam." 2019.
[4] U.S. Food and Drug Administration. "Controlled Substance Schedules." 2022.
[5] MarketResearch.com. "Sleep Aids Market Forecast." 2023.

---

This analysis aims to inform stakeholders on the current state and future prospects of Estazolam, guiding strategic decisions in research, clinical use, and market entry.